Scientific deep-dive

How Long Is the Evidence, Actually?

These are indefinite treatments. In the largest randomized trial at the weight indication, the mean time on the drug was 34.2 months. What the long trials ran for, and what a short evidence base does and does not mean.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
7 min read·5 citations

These medicines are prescribed as indefinite treatment. Stop and the weight returns; every trial of stopping has found that. So the plan, stated or not, is usually “continue”. How much of that indefinite future has anyone observed? In the largest and longest randomized trial at the weight indication, the mean time participants spent taking the drug was 34.2 months.[2] That is just under three years.

What the long trials ran for

The longest randomized evidence on GLP-1 medicines. Durations copied from each trial's published report. Note what kind of duration each figure is.
TrialDrug and populationDuration
STEP 5[1]Semaglutide 2.4 mg, overweight or obesity without diabetes104 weeks (2 years)
SELECT[2]Semaglutide 2.4 mg, 17,604 adults with obesity and cardiovascular disease, without diabetesMean exposure 34.2 months; mean follow-up 39.8 months
SUSTAIN-6[4]Semaglutide, type 2 diabetes104 weeks (2 years)
LEADER[3]Liraglutide, type 2 diabetesMedian follow-up 3.8 years
Exposure and follow-up are not the same number, and the difference matters here. SELECT followed people for a mean of 39.8 months but they were taking the drug for a mean of 34.2, because people stop and the trial keeps watching. Quoting the follow-up figure as “time on the drug” overstates the drug evidence by more than five months, and it is the commonest way this gets reported.

So the weight-indication evidence runs to roughly two to three years, and for the drugs prescribed for weight, the longest randomized follow-up is about four years: SURPASS-CVOT followed people on tirzepatide or dulaglutide for a median of 4.0 years, in type 2 diabetes.[5] For a treatment framed as ongoing, that is the whole of what has been watched.

Why the diabetes trials do not simply fill the gap

GLP-1 medicines have been prescribed in type 2 diabetes far longer than they have for weight, and it is tempting to treat that history as reassurance that covers everything. Partly it does. LEADER randomized people to liraglutide with a median follow-up of 3.8 years, and it is a real long-duration safety dataset.[3]

But it does not transfer cleanly. Those trials studied a different population, at different doses, for a different purpose. Semaglutide at 2.4 mg for weight is a substantially higher dose than the diabetes trials used, and the people taking it are on average healthier and younger. Reassurance from one setting is worth something in the other; it is not the same as having been measured there.

What a short evidence base does and does not mean

This is the part that gets distorted in both directions.

  • It does not predict harm. No signal has emerged at three years that was invisible at one. Nothing here is a reason to expect something to go wrong at year five.
  • It does mean the answer is unknown, to everyone, including your prescriber and including us. Ten-year data on semaglutide at the weight dose does not exist because ten years have not passed.
  • The comparison is not against certainty. Living with untreated obesity has its own long-term outcomes, and they are well characterized and not good. A short evidence base on a treatment is not automatically worse than a long evidence base on the alternative.
  • The cardiovascular finding is real and came from the long trial. In SELECT, a primary cardiovascular event occurred in 6.5% on semaglutide against 8.0% on placebo.[2] Long trials are how benefits of that kind get found at all.
What happens at ten years is unknown to everyone, because ten years have not passed.

What this means for your decision

The practical consequence is not “do not take it”. It is that the indefinite part of indefinite treatment should be a conversation, held early, with someone who knows your history, rather than something you discover at the point where the supply or the money stops.

Two things follow from that. First, whether you can keep getting it is a clinical question and not only a financial one, because stopping has a predictable result: our what happens when you stop covers the trial evidence, and the price tracker keeps a dated figure for every seller we follow. Second, being on a treatment whose long-term record is still being written is a reason for ordinary monitoring, not alarm.

New readouts keep arriving. Extension studies and outcome trials in kidney disease, heart failure and liver disease are steadily lengthening the record. Our trial tracker follows what is running and what has reported.

Frequently Asked Questions

The randomized evidence at the weight indication runs to roughly two to three years. STEP 5 ran 104 weeks. SELECT, the largest, had a mean drug exposure of 34.2 months and a mean follow-up of 39.8 months across 17,604 people.
Not at the weight-management dose, because ten years have not passed since it came into use. For the drugs prescribed for weight, the longest randomized follow-up is about four years: LEADER ran a median 3.8 years on liraglutide and SURPASS-CVOT a median 4.0 years on tirzepatide, both in type 2 diabetes.
Partly, and not cleanly. They studied a different population at different doses for a different purpose; semaglutide 2.4 mg for weight is a higher dose than the diabetes trials used. That history is real reassurance, but it is not the same as having been measured in this setting.
No. It means the answer is unknown rather than concealed, and no signal has appeared at three years that was invisible at one. And the comparison is not against certainty: untreated obesity has its own well-characterized long-term outcomes.
Exposure is time spent taking the drug; follow-up is time the trial kept watching, including after people stopped. In SELECT those were 34.2 and 39.8 months. Reporting the follow-up figure as time on the drug overstates the evidence by more than five months, and it happens often.

References

  1. 1.Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial Nature Medicine. 2022. PMID: 36216945.
  2. 2.Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes New England Journal of Medicine. 2023. PMID: 37952131.
  3. 3.Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes New England Journal of Medicine. 2016. PMID: 27295427.
  4. 4.Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes New England Journal of Medicine. 2016. PMID: 27633186.
  5. 5.Zoungas S, D'Alessio D, Pavo I, et al. A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified analysis of SURPASS-CVOT The Lancet Diabetes & Endocrinology. 2026. PMID: 42114520.

GLP-1 Drugs, Testosterone and Male Fertility: Where the Evidence Splits

In a randomized comparison, semaglutide improved sperm morphology while testosterone replacement significantly reduced sperm counts, though both raised testosterone.

7 min read

The Cochrane Verdict, and Who Funded the Evidence

Two WHO-funded Cochrane reviews find weight loss likely to be sustained; the semaglutide review calls it clinically relevant. Both also note the trials were paid for by the manufacturers: all of them, in tirzepatide's case.

6 min read

GLP-1 Drugs and Hidradenitis Suppurativa: Early Studies, No Trial

Early studies of liraglutide and semaglutide report improvement in HS severity and quality of life. There is no randomized trial, and weight loss by other means has had mixed results in this condition, which complicates the obvious explanation.

5 min read

GLP-1 Drugs and HIV-Associated Lipohypertrophy: The Randomized Evidence

A phase 2b randomized trial found once-weekly semaglutide cut abdominal visceral fat by about 30.6% over 32 weeks in people with HIV-associated lipohypertrophy, alongside a 9.3% fall in psoas muscle volume that did not cost measurable function.

6 min read

GLP-1s and Fatty Liver: What the Phase 3 Trial Showed

Semaglutide resolved steatohepatitis in 62.9% of patients, against 34.3% on placebo. The difference is 28.7 points. In the one trial in compensated cirrhosis, it produced neither resolution nor fibrosis improvement.

7 min read

GLP-1 Drugs for PCOS: Eleven Trials, and Two Analyses That Disagree

No GLP-1 is approved for PCOS anywhere. The randomized evidence is eleven trials: a low-certainty weight effect, better insulin sensitivity than metformin, and reproductive outcomes two meta-analyses grade differently.

8 min read

Where to get semaglutide online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

6.3

WellMedRx

Comparing compounded and brand GLP-1 plans with a published state list

6.6

HumeCare+

An oral route if you will not self-inject

9.1

Collective

From $59/mo + membership

Get started →
Read full review →

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →